Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 multicenter, double-blind, randomized, placebo-controlled, two-arm study
for subjects with locally recurrent or metastatic triple negative breast cancer.